Evidence-based decision making about Hib vaccination
Abstract
In response to the results of the Lombok Haemophilus influenzae type b (Hib) vaccine probe trial (Jan 1, p 43),1 Ana Lucia Sgambatti de Andrade and Celina Turchi Martelli (p 5)2 ask 鈥淗ow much evidence is sufficient for policy makers?鈥� In July, 2004, the Global Alliance for Vaccines and Immunization (GAVI) established a Task Force to explore how countries can be supported to make evidence-based decisions on the introduction and continued use of Hib-containing vaccines. Since then, the Task Force has undertaken a country consultation process, and explored issues related to programmes, supply, and financing associated with Hib vaccination in three groups of countries: those that have or are about to introduce Hib vaccine (Kenya, Ghana, Malaysia, Mongolia); those that are eligible for Hib but have not applied (Cameroon, Mozambique); and those considered to have an unclear disease burden (Bangladesh, Uzbekistan).
Citation
Lancet(2005) 365 (9463) 936-937 [doi:10.1016/S0140-6736(05)71076-X]